Please assess the completion status of the following clinical trial:

Trial Title: Prucalopride for Postoperative Ileus in Patients Undergoing Gastrointestinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Consecutive patients undergoing elective gastric, small bowel, or partial colonic resection via laparotomy or laparoscopy.~2. Patients with American Society of Anaesthesiologists grading I-III~3. Informed consent available.~Exclusion Criteria:~1. Patients with stoma creation, extensive adhesiolysis, total or subtotal colectomy , or patients who had a history of total or subtotal colectomy.~2. Patients who developed intraoperative problems or complications, or had peritoneal carcinomatosis.~3. Patients who developed serious complications within 24 hours after surgery.~4. Those who received epidural anesthesia or analgesia.~5. Patients who received other prokinetic drugs.~6. Patients who were allergic to prucalopride.~7. Patients with severe comorbidity and/or organ(kidney, liver, and heart) dysfunction~8. Patients had complete bowel obstruction~9. Patients who have participated other clinical trials.~10. Patients who have short bowel(\<200cm small bowel) or history of constipation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prucalopride (Type: EXPERIMENTAL): Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
- Placebo (Type: PLACEBO_COMPARATOR): Vitamin C, 50mg, tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).